Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome

PURPOSE: Sapacitabine is an oral deoxycytidine nucleoside analog with a unique mechanism of action that is different from cytarabine. PATIENTS AND METHODS: To define the dose-limiting toxicities (DLT) and maximum-tolerated dose (MTD) of sapacitabine given orally twice daily for 7 days every 3 to 4 w...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kantarjian, Hagop, Garcia-Manero, Guillermo, O'Brien, Susan, Faderl, Stefan, Ravandi, Farhad, Westwood, Robert, Green, Simon R., Chiao, Judy H., Boone, Patricia A., Cortes, Jorge, Plunkett, William
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2010
Materias:
Original Reports
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3340938/
https://ncbi.nlm.nih.gov/pubmed/19933907
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.0209
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares